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Abstract
Background: Prognosis of esophageal cancer is poor despite curative surgery. The chemokine receptor CXCR4 has
been proposed to distinctly contribute to tumor growth, dissemination and local immune escape in a limited number of
malignancies. The aim of our study was to evaluate the role of CXCR4 in tumor spread of esophageal cancer with a
differentiated view of the two predominant histologic types – squamous cell and adenocarcinoma.
Methods: Esophageal cancer tissue samples were obtained from 102 consecutive patients undergoing esophageal
resection for cancer with curative intent. The LSAB+ System was used to detect the protein CXCR4. Tumor samples
were classified into two groups based on the homogeneous staining intensity. A cut-off between CXCR4w (= weak
expression) and CXCR4s (= strong expression) was set at 1.5 (grouped 0 – 1.5 versus 2.0 – 3). Long-term survival rates
were calculated using life tables and the Kaplan-Meier method. Using the Cox's proportional hazards analysis, a model
of survival prediction was established.
Results: The overall expression rate for CXCR4 in esophageal squamous cell carcinoma was 94.1%. Subdividing these
samples, CXCR4w was found in 54.9% and CXCR4s in 45.1%. In adenocarcinoma, an overall expression rate of 89.1%
was detected with a weak intensitiy in 71.7% compared to strong staining in 29.3% (p = 0.066 squamous cell versus
adenocarcinoma). The Cox's proportional hazards analysis identified the pM-category with a hazard ratio (HR) of 1.860
(95% CI: 1.014–3.414) (p = 0.045), the histologic tumor type (HR: 0.334; 95% CI: 0.180–0.618) (p = 0.0001) and the
operative approach (transthoracic > transhiatal esophageal resection) (HR: 0.546; 95% CI: 0.324–0.920) (p = 0.023) as
independent factors with a possible influence on the long-term prognosis in patients with esophageal carcinoma, whereas
CXCR4 expression was statistically not significant (>0.05).
Conclusion: Expression of the chemokine receptor CXCR4 in esophageal cancer is of major relevance in both
histologic entities – squamous cell and adenocarcinoma. Though with lack of statistical significance, strong CXCR4
expression revealed a poorer long-term prognosis following curative esophagectomy in both histologic subtypes. Thus,
the exact biological functions of CXCR4 in terms of tumor dissemination of esophageal cancer is yet undetermined.
Inhibition of esophageal cancer progression by CXCR4 antagonists might be a promising therapeutic option in the future.
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Background
Due to a highly malignant potential for lymph node
metastasis and vascular invasion, long-term prognosis of
esophageal carcinoma still is – despite curative surgery –
poor with 5-year survival rates of 30% reported even
recently [1]. Squamous cell carcinoma and adenocarci-
noma of the esophagus exhibit a different biological
behaviour, pathogenesis and location, establishing the
two tumor types as separate entities [2,3]. Various studies
have described the histologic differentiation as an inde-
pendent prognostic factor after surgical R0-resection [4,5].
Tumor spread, at least in advanced stages, in esophageal
adenocarcinoma is characterized by distant metastases as
compared to squamous cell carcinoma with a tendency
towards local infiltrative growth [6].
Chemokines are a family of chemoattractant proteins that
are classified depending on the arrangement of amino
acids adjacent to conserved cysteine residues. CXCR4 is a
seven-transmembrane G protein-coupled receptor and is
also known as a coreceptor for HIV. SDF-1α (stem cell
derived factor α), the natural ligand for CXCR4, is a mem-
ber of the CXC chemokine family that has chemotactic
activity for hematopoietic progenitor cells [7-10]. Thus
far, chemokine signalling results in the transcription of
target genes that are involved in cell invasion, motility,
interactions with the extracellular matrix (ECM) and sur-
vival [11]. The expression of the chemokine receptor
CXCR4 has been shown to play key mechanisms in migra-
tion and metastasis with associated tumor progression
and poor prognosis in a limited number of malignancies
[12-15].
The role of chemokine receptors in tumor spread of
esophageal cancer with a differentiated view of the two
predominant histologic types yet has to be determined.
Methods
Esophageal resection and tissue samples
Esophageal cancer tissue samples were obtained from 102
consecutive patients undergoing esophageal resection for
cancer with curative intent at the Department of General
and Abdominal Surgery, University of Mainz between
1999 and 2003. The study has been approved by the local
ethics committee. Squamous cell carcinoma was diag-
nosed in 53 and adenocarcinoma in 49 patients. Patients
with undifferentiated carcinoma or other malignant
tumors of the esophagus as well as patients with neoadju-
vant chemoradiotherapy were excluded from the study.
Abdominothoracic esophagectomy (60.4%) was rou-
tinely performed for squamous cell carcinoma. A transhi-
atal procedure (37.0%) was selected for tumors with a
distal location and malignancies without esophageal wall
penetration, or in the presence of a high general operative
risk. Transhiatal esophagectomy with abdominal and pos-
terior mediastinal lymphadenectomy was carried out in
79.6% of adenocarcinomas, whereas the two-field proce-
dure was done in 18.4% in the presence of advanced
tumor growth or extended lymph node involvement. His-
topathologic examination of the surgical specimens
revealed the tumor-node metastasis classification of the
International Union Against Cancer [16]. pM1 patients
were defined as positive lymph node metastases at the
celiac trunk (pM1 lymph). These lymph node metastases
were cleared in all cases with a consecutive R0 resection.
Immunohistochemical staining
The LSAB+ System from DakoCytomation (K0690; Dako-
Cytomation Inc., California, USA) was used to detect the
protein CXCR-4 (anti-CXCR-4, CIO115, dilution 1:200;
Capralogics, USA). In brief, samples were exposed to
70°C for one hour in a humified oven and hereafter
deparaffinised. After pre-incubation with hydrogen perox-
ide (3%) for 5 minutes and consecutive incubation with
human fresh frozen plasma for one hour, the primary
antibodies were applied for 2 hours at room temperature.
After incubation with the secondary antibody (pooled
swine-anti-goat, -anti-mouse, -anti-rabbit-antibody;
LSAB+ Kit) for 15 minutes, the samples were exposed to
streptavidinperoxidase for another 15 minutes and chro-
mogen-solution (LSAB+ solution) for 15 minutes (LSAB+
Kit, respectively). Counterstaining was performed with
haematoxylin (Sigma, Germany). For negative controls
only the secondary antibody was used. A negative control
was performed for each esophageal cancer sample. For
positive controls, formalin-fixed and paraffin-embedded
tissue samples of the human spleen were applied.
Evaluation of Immunostaining
Immunostaining was evaluated by three authors inde-
pendently, blinded to the patients' clinicopathological
features and long-term survival. The immunohistochemi-
cal staining was analyzed according to a scoring method
previously validated. Tumor samples were classified into
two groups based on the homogeneous staining intensity:
0 = absent, 1 = weak, 2 = intermediate, 3 = strong staining.
In the case of heterogeneous staining within the sample,
the respective 0.5 points higher score was chosen, if more
than 50% of cells revealed the higher staining intensity. If
evaluations did not agree, specimens were reevaluated
and re-classified according to the assessment given most
frequently by the observers. A cut-off between CXCR4w (=
weak expression) and CXCR4s (= strong expression) was
set at 1.5 (grouped 0 – 1.5 versus 2.0 – 3).
Statistical analysis
The SPSS 12.0 software package was used for statistical
data analysis (SPSS, Chicago, IL, USA: 2005). Clinical data
were prospectively collected in a database established for
internal quality control and retrospectively analysed. TheBMC Cancer 2006, 6:290 http://www.biomedcentral.com/1471-2407/6/290
Page 3 of 7
(page number not for citation purposes)
presented data are expressed as mean values (+/- standard
deviation). In the comparative analysis of the different
parameters between the two CXCR4 expression groups,
the χ2 test with Pearson's correction with cross-table calcu-
lations, or the Fisher's exact test was used for categorical
parameters. The Mann-Whitney U-test served as the non-
parametric method for quantitative variables. Long-term
survival data were finally recorded in December 2005 and
collected by telephone interview with the patients or their
primary physicians. Survival probabilities were estimated
using life tables and the method of Kaplan and Meier, and
a log-rank analysis was carried out to determine signifi-
cant differences between the patient groups. The Cox's
univariate regression model was used to analyse the influ-
ence of possible prognostic factors on survival separately.
Multivariate analysis of significant factors was performed
using Cox's proportional hazards model. A p-value of
<0.05 was considered statistically significant for all proce-
dures.
Results
Patterns of CXCR4 expression in squamous cell carcinoma 
(SCC) and adenocarcinoma (ADC) of the esophagus
Staining for CXCR4 revealed predominantly a cytoplas-
matic, and in a few specimens a weak membranous loca-
tion of CXCR4. The respective overall expression rate for
CXCR4 in squamous cell carcinoma was 94.1%. Subdivid-
ing these samples according to the previous classification,
CXCR4w was found in 54.9% and CXCR4s in 45.1% (Fig-
ure 1a–c). In adenocarcinoma, an overall expression rate
of 89.1% was detected with a weak intensitiy in 71.7%
compared to strong staining in 29.3% (Figure 2a–c).
There was no statistical significant difference in the inten-
sity patterns of chemokine receptor expression between
the two histologic tumor types (p = 0.066).
Clinical features and CXCR4 expression
There were no significant differences between the two
classes of CXCR4 expression (CXCR4w versus CXCR4s) in
squamous cell carcinoma as well as in adenocarcinoma
with regard to age, gender ASA-classification and tumor
location (Table 1)
Histopathologic characteristics and CXCR4 expression
In patients with squamous cell carcinoma, a significant
difference between the two groups of CXCR4 expression
was found for tumor grading (p = 0.030). Differences in
CXCR4 intensity (CXCR4w versus CXCR4s) were not sig-
nificant reflecting the T-, N-, and M-category (Table 2).
Other parameters included in the analysis – separately for
both tumor types – as tumor size, UICC-classification,
lymphangiosis carcinomatosa and lymph node ratio
(involved lymph nodes × 100/dissected lymph nodes)
revealed no significant differences in CXCR4 expression.
Long-term survival and CXCR4 expression
In squamous cell carcinoma, patients with a weak CXCR4
expression had a mean survival of 25 (+/- 5 SD) months
after surgery as compared to only 17 (+/- 4 SD) months in
the group with strong chemokine expression (Figure 3).
However, this difference was statistically not significant
(log-rank test: p = 0.2491). Patients with adenocarcinoma
and CXCR4w  had a mean survival of 32 (+/- 4 SD)
months while the CXCR4s group did not significantly dif-
fer in prognosis with 31 (+/- 6 SD) months after esopha-
geal resection (log-rank test: p = 0.6080) (Figure 4).
For multivariate analysis, a model of prediction of sur-
vival time was established using the Cox's proportional
hazards analysis. Variables selected for this model were:
CXCR4 expression, pT-, pN-, pM-category, histologic
tumor type, tumor grading and the operative procedure
(transthoracic versus transhiatal esophageal resection).
The analysis identified the pM-category with a hazard
ratio (HR) of 1.860 (95% CI: 1.014–3.414) (p = 0.045),
the histologic tumor type (HR: 0.334; 95% CI: 0.180–
0.618) (p = 0.0001) and the operative approach (HR:
a-c. CXCR4-expression in squamous cell carcinoma with  weak (CXCR4w) (a) and strong (CXCR4s) (b) staining inten- sity compared to negative control (c) Figure 1
a-c. CXCR4-expression in squamous cell carcinoma with 
weak (CXCR4w) (a) and strong (CXCR4s) (b) staining inten-
sity compared to negative control (c).
a
b
cBMC Cancer 2006, 6:290 http://www.biomedcentral.com/1471-2407/6/290
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0.546; 95% CI: 0.324–0.920) (p = 0.023) as independent
factors with a possible influence on the long-term progno-
sis in patients with esophageal carcinoma (Table 3).
Discussion
CXCR4 expression was detected in both types of esopha-
geal cancer – squamous cell and adenocarcinoma. A
slightly higher expression of CXCR4 (94.1% in squamous
cell carcinoma and 89.1% in adenocarcinoma of the
esophagus) was found as compared to other studies. Our
data provide evidence that expression of CXCR4 by pri-
mary tumor cells is associated with malignant transforma-
tion in esophageal cancer, consistent with recent findings
by Kaifi et al [17], but contrasted to a preceding investiga-
tion of Mitra et al., who used reverse transcriptase-
polymerase chain reaction [18]. The only study investigat-
ing CXCR4 expression in esophageal squamous cell and
adenocarcinoma of the esophagus before- to our knowl-
edge – has been published by Kaifi et al [17]. Thus, the dif-
ference in the tumor-biologic behaviour of the two
esophageal cancer types with a high incidence rate of loco-
regional spread in squamous cell carcinoma as compared
to the development of distant metastasis in adenocarci-
noma is not yet fully understood.
Although the exact mechanism of CXCR4 activity has not
thoroughly been elucidated, it may induce or support car-
cinogenesis through the interaction of CXCR4 with its lig-
and SDF-1α, which mediates the activation of
phosphatidylinositol 3-kinase and Akt, resulting in cell
proliferation [19,20]. Interestingly, CXCR4 is regulated by
different external factors, such as hypoxia (hif-1- path-
way) and the activation of adenosine-receptors, as well as
by internal alterations as the inactivation of tumor sup-
pressor genes pVHL, p53, over-expression of NFkB and
DNA methylation [21-25]. Homing factors, inducing
chemotaxis to target organs of dissemination, have been
proposed as the major inductor of tumour cell dissemina-
tion and metastatic growth, as the filter theory does not
sufficiently explain the growth of metastases in target
organs [26-28]. SDF-1α, which is produced elsewhere, is
most intense in typical "homing organs" such as lungs,
bone marrow, liver and lymph-nodes compared with
other non-homing tissues [14,17]. The interaction
between esophageal cancer-expressed CXCR4 and SDF-1α
may be a key event in directing malignant cells to these
"homing organs", and this mechanism may also account
for metastasis from other organs, as previously reported
[29-31]. This homing theory is underlined by the find-
ings, that the presence of micrometastatic tumor cells in
lymph nodes and bone marrow has been associated with
poorer survival [32,33].
In our study, the CXCR4 expression profile did not differ
significantly between squamous cell carcinoma and aden-
ocarcinoma in esophageal cancer, proposing additional
factors responsible for their different patterns of tumor
spread. It may also support the hypothesis of a similar
pathway of CXCR4's influence on the lymphatic and
hematogeneous tumor cell dissemination. Although the
interaction of CXCR4 with the lymphatic system has not
been investigated as intense as the hematogeneous dis-
semination, CXCR4 inhibition resulted in suppression of
breast cancer lymph node metastases, implying common
routes in both systems [34].
In both histologic types, strong CXCR4 expression
revealed a poorer long-term prognosis following
esophagectomy in curative intent. Thus, CXCR4 was not
significantly associated with survival in contrast to a
recent study by Kaifi et al, published in the Journal of the
National Cancer Institute, 2005. Though a lack of statistical
significance, there was a trend to a less favourable out-
come associated with an increased intensity of CXCR4, as
has previously been demonstrated for other malignancies
[12-15]. The histologic tumor type in the Cox regression
analysis was statistically significant (p = 0.0001), which
a-c. CXCR4-expression in adenocarcinoma with weak  (CXCR4w) (a) and strong (CXCR4s) (b) staining intensity  compared to negative control (c) Figure 2
a-c. CXCR4-expression in adenocarcinoma with weak 
(CXCR4w) (a) and strong (CXCR4s) (b) staining intensity 
compared to negative control (c).
a
b
cBMC Cancer 2006, 6:290 http://www.biomedcentral.com/1471-2407/6/290
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Kaplan-Meier survival curves for patients with adenocarci- noma and weak (CXCR4w) versus strong (CXCR4s) chem- okine receptor expression Figure 4
Kaplan-Meier survival curves for patients with adenocarci-
noma and weak (CXCR4w) versus strong (CXCR4s) chem-
okine receptor expression.
p=0.6080
Kaplan-Meier survival curves for patients with squamous cell  carcinoma and weak (CXCR4w) versus strong (CXCR4s)  chemokine receptor expression Figure 3
Kaplan-Meier survival curves for patients with squamous cell 
carcinoma and weak (CXCR4w) versus strong (CXCR4s) 
chemokine receptor expression.
p=0.2491
Table 2: Histopathologic characteristics and CXCR4-expression.
SCC ADC
CXCR4w CXCR4s p-value CXCR4w CXCR4s p-value
pT-category
-pT1-2 17.9 21.7 0.857 48.5 38.5 0.856
-pT3-4 82.1 78.3 51.5 61.5
pN-category
-pN0 46.4 34.8 0.290 21.2 15.4 0.845
-pN+ 53.6 65.2 78.8 84.6
pM-category
-pM0 85.7 73.9 0.261 69.7 84.6 0.259
-pM+ 14.3 26.1 30.3 15.4
tumor grading
-G1-2 32.1 65.2 0.030* 27.3 46.2 0.315
-G3-4 67.9 34.8 72.7 53.8
*statistically significant
Table 1: Clinical features and CXCR4-expression.
SCC ADC
CXCR4w CXCR4s p-value CXCR4w CXCR4s p-value
age (years) 56.8 (+/- 7.5 SD) 58.4 (+/- 8.5 SD) 0.501 62.0 (+/-10.3 SD) 59.3 (+/- 6.9 SD) 0.131
gender (% males) 89.3 87.0 0.566 87.9 92.3 0.561
ASA (%)
-I 32.1 30.4 0.973 69.7 46.2 0.067
-II 60.7 65.3 27.3 46.2
-III 7.2 4.3 3.0 7.6
tumor location (%)
-proximal 1/3 10.7 13.0 0.712 0 0 0.499
-middle 1/3 50.0 52.2 3.0 7.7
-distal 1/3 39.3 34.8 97.0 92.3BMC Cancer 2006, 6:290 http://www.biomedcentral.com/1471-2407/6/290
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might be explained by the different biological behaviour
associated with squamous cell and adenocarcinoma as
published before (Gockel I, et al. World J Surg
2006;30:183–190) [6]. Apart from the histologic tumor
type, the pM-category proved an independent prognostic
factor using Cox's proportional hazards model. Although
all patients with pM1 (lymph) (= celiac trunk positive
lymph node metastases) had undergone curative resec-
tion, this emphasizes the impact of systemic disease on
impaired survival. The surgical procedure was another sig-
nificant parameter in this analysis with a more favourable
outcome following the transthoracic esophagectomy with
extended lymphadenectomy, at least in patients with
squamous cell carcinoma, as recently published [35].
Conclusion
Expression of the chemokine receptor CXCR4 in esopha-
geal cancer is of major relevance in both histologic entities
– squamous cell and adenocarcinoma. Though with lack
of statistical significance, strong CXCR4 expression
revealed a poorer long-term prognosis following curative
esophagectomy in both histologic subtypes. The type of
the surgical resection in esophageal cancer remained one
of the most important factors with an influence on the
patients' long-term prognosis.
Thus, the exact biological functions of CXCR4 in terms of
tumor dissemination of esophageal cancer is yet undeter-
mined. Inhibition of esophageal cancer progression by
CXCR4 antagonists might be a promising therapeutic
option in the future.
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